ARTA
AUPH icon

A.R.T. Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

A.R.T. Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-60,695
Closed -$1.23M – 124
2019
Q4 		$1.23M Buy
60,695
+48,800
+410% +$450K 0.06% 471
2019
Q3 		$64K Sell
11,895
-6,500
-35% -$39.3K ﹤0.01% 1295
2019
Q2 		$121K Buy
18,395
+5,700
+45% +$36.3K 0.01% 1166
2019
Q1 		$83K Buy
+12,695
New +$84.2K 0.01% 1189
2018
Q3 		– Sell
-55,595
Closed -$312K – 1391
2018
Q2 		$312K Buy
+55,595
New +$310K 0.01% 1092
2018
Q1 		– Sell
-66,365
Closed -$300K – 1484
2017
Q4 		$300K Buy
+66,365
New +$368K 0.01% 1055
2017
Q3 		– Sell
-97,600
Closed -$598K – 1350
2017
Q2 		$598K Buy
97,600
+58,200
+148% +$392K 0.03% 728
2017
Q1 		$289K Buy
+39,400
New +$182K 0.01% 1019

Other funds holding AUPH

HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

A.R.T. Advisors's AUPH Position: Q1 2020 in Review

A.R.T. Advisors sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2020, closing a stake of 60,695 shares — an estimated $1.23M sold.

A.R.T. Advisors first reported a position in AUPH in Q1 2017 and held it in 8 quarters. The position peaked at $1.23M in Q4 2019. 125 funds tracked by Wall St. Rank hold AUPH as of Q1 2020.

  • A.R.T. Advisors reported no remaining Aurinia Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 60,695 Aurinia Pharmaceuticals shares in Q1 2020, an estimated $1.23M.
  • A.R.T. Advisors first reported a position in Aurinia Pharmaceuticals in Q1 2017 and held it in 8 quarters.
  • A.R.T. Advisors's Aurinia Pharmaceuticals position peaked at $1.23M in Q4 2019.
  • 125 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.